ELV
Elevance Health Inc.
NYSE · Healthcare · Medical - Healthcare Plans · US
$407.50
−1.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 201.1B | 199.1B | 176.8B | 171.3B | 156.6B |
| Cost of Revenue | 122.8B | 148.2B | 127.6B | 124.3B | 116.6B |
| Gross Profit | 78.3B | 50.9B | 49.2B | 47.0B | 40.0B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 6.3B | — | — | — | — |
| General & Admin Expense | 6.3B | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 64.9B | 42.8B | 40.4B | 38.3B | 31.5B |
| Total Operating Expenses | 71.3B | 42.8B | 40.4B | 38.3B | 31.5B |
| Cost and Expenses | 194.1B | 191.0B | 167.9B | 162.6B | 148.1B |
| Operating Income (EBIT) | 7.1B | 8.1B | 8.9B | 8.7B | 8.5B |
| Non-Operating | |||||
| Interest Income | 704.0M | — | — | — | — |
| Interest Expense | 1.1B | 1.4B | 1.2B | 1.0B | 851.0M |
| Net Interest Income | (426.0M) | (1.4B) | (1.2B) | (1.0B) | (851.0M) |
| Other Non-Op Income/Expense | (1.2B) | (1.4B) | (984.0M) | (1.0B) | (851.0M) |
| Non-Operating Income (excl Interest) | 70.0M | — | (201.0M) | — | — |
| EBT (Pre-Tax Income) | 5.9B | 6.7B | 7.9B | 7.7B | 7.6B |
| Income Tax Expense | 915.0M | 1.0B | 1.9B | 1.7B | 1.7B |
| Bottom Line | |||||
| Net Income | 5.0B | 5.7B | 6.0B | 6.0B | 5.9B |
| Earnings from Cont. Ops | 4.9B | 5.7B | 6.0B | 6.0B | 5.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.0B | 5.7B | 6.0B | 6.0B | 5.9B |
| Per Share | |||||
| Basic EPS | $22.50 | $25.18 | $25.81 | $25.38 | $24.56 |
| Diluted EPS | $22.50 | $25.12 | $25.68 | $25.22 | $24.28 |
| Revenue Per Share | $922.96 | $897.77 | $759.28 | $735.14 | $652.48 |
| Shares | |||||
| Basic Shares Outstanding | 217.9M | 221.8M | 232.9M | 233.1M | 240.0M |
| Diluted Shares Outstanding | 217.9M | 221.8M | 232.9M | 237.4M | 242.8M |
| Profitability Metrics | |||||
| EBITDA | 8.0B | 9.7B | 10.5B | 10.5B | 10.1B |
| D&A | 1.0B | 1.5B | 1.4B | 1.7B | 1.7B |
| EBIT | 7.0B | 8.1B | 9.1B | 8.7B | 8.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026